- Solid Tumors
- Pipeline Molecules
- Alliance Partners
Our mission is to provide healthcare professionals with unbiased clinical research information, easily.
Currently, you can access the following clinical trials being conducted worldwide:
Clinicaltrials.gov identifier NCT03941626
Recruitment Status Recruiting
First Posted May 8, 2019
Last update posted July 11, 2019
This is a single arm, open-label, uni-center, phase I-II study to evaluate the safety and effectiveness of CAR-T/TCR-T cell immunotherapy in treating with different malignancies patients.
The study is a multi-target gene-modified immunotherapy. CAR-T/TCR-T cells include four different tumor-specific antibody.They are as following:anti-NY-ESO-1 antibody foresophagus cancer;anti-DR5 antibody for hepatoma;;anti-EGFR vIII antibody for hepatoma and glioma;anti-Mesothelin antibody for gastric cancer.
|Experimental: CAR-T/TCR-T cells immunotherapy
Enrolled patients will receive CAR-T cell immunotherapy with several different specific Chimeric antigen receptors aiming at different antigens respectively by infusion.
Biological: CAR-T/TCR-T cells immunotherapy
According to tumor burden and other conditions, patients will be treated with cyclophosphamide or fludarabine,then,CAR-T cells will be infused 48-72 hours later.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, , Learn About Clinical Studies.-->
1. Patients must be willing to sign an informed consent.
2. Male or female patients aged 18 to 70 years .
3. Estimated survival of ≥ 12 weeks.
4. Pathological sections with positive expression of NY-ESO-1, Mesothelin, EGFRvIII and
DR5 was confirmed by biopsy IHC test within 12 months.If NY-ESO-1 is positive
expression ,positive HLAA*0201 is required at the same time.
5. Solid tumor must have at least one measureable disease according to RECIST 1.1.
6. Routine blood test#hemoglobin>=90 g/L; platelet>=50×10^9/L.
7. Liver function:ALT and AST≤2.5 times upper limits of normal (If the tumor infiltration
is the main cause of abnormal liver function ,ALT and AST≤5 times upper limits of
11. ECOG score:0-1.
12. Adequate venous access for apheresis, and no other contraindications for leukapheresis
13. Women of child-bearing age must have evidence of negative pregnancy test. Subjects of
reproductive potential must agree to use acceptable birth control methods within 1
year after treatment, as described in protocol.
14. Subjects with hypertension/diabetes must be stable blood pressure/blood glucose or
≤CTCAE 1 level 2 weeks before the screening.
In addition to the above criteria for inclusion, the following criteria shall be met
according to the indications:
Patients with glioblastoma：
1. First disease progression or disease recurrence (≥ 1 cm and ≤ 5 cm) of a
supratentorial WHO grade IV malignant glioma (GBM or gliosarcoma) based on imaging
studies with measurable disease.
2. EGFRvIII, the target antigen, must be identified on tumor tissue by IHC or PCR, i.e.
EGFRvIII positive via pathology report.
3. Insensitivity to chemoradiotherapy or chemoradiotherapy failure after operation
4. Refused to receive radiotherapy or chemotherapy treatment.
Patients with liver cancer
1. DR5 or EGFRvIII positive via pathology report.
2. Untreatable by surgery ; Or postoperative recurrence ;Or no effective treatment.
3. Liver function：child-pugh A grade or child-pugh B grade.
Patients with gastric cancer
1. Mesothelin positive via pathology report.
2. The pathological stage：IIIA～IV.
3. chemoradiotherapy failure
4. Refused or unable to get surgery.
Patients with esophageal cancer
1. NY-ESO-1 positive via pathology report and HLA-A*0201 positive in blood.
2. Refuse or unable to get surgery.
3. Postoperative recurrence or chemoradiotherapy failure.
2. malignant tumor cells with T cell origin via pathology test.
3. Organ failure: stage III or IV congestive heart failure; Renal failure and uremia;
respiratory failure; disturbance of consciousness.
4. Acute or chronic GVHD after allogeneic hematopoiesis; Or being treated for GVHD; Or
hormone or immunosuppressant used within 30 days
5. steroid hormoneswere used before and after blood collection and infusion
6. Patients with HIV infection or active hepatitis
7. Uncontrolled active infection.
8. Enrolled to other clinical study in the last 4 weeks.
9. Patients with systemic auto-immune disease or immunodeficiency.
10. Patients with neuropathy or psychosis, including dementia or epilepsy, or history of
psychotropic substance abuse, or other substantial lesions that may increase central
11. Concomitant with the second tumor or other malignant tumors.
12. Patients with bone metastases are at risk of a pathological fracture resulting in
paraplegia or life threatening.
13. Live attenuated vaccine was administered within 4 weeks prior to blood collection.
14. Blood oxygen saturation is maintained by oxygen inhalation.
15. Received major surgery within 2 weeks prior to screening ;Or Plan to receive surgery
during study or within 2 weeks after injection.
16. Other patients that researchers considered unsuitable for inclusion.
Contact: ZHONG HUA YANG +8618938688105 ext +8618938688105 firstname.lastname@example.org
Henan Provincial People's Hospital
Shenzhen BinDeBio Ltd.
Henan Provincial People's Hospital